Pimafucin, 100 mg 20 pcs

Antifungal polyene (tetraene) antibiotic from the macrolide group. It has a predominantly fungicidal effect. Natamycin irreversibly binds to the ergosterol of the cell membrane of the fungus, which leads to violation of its integrity, loss of cytoplasmic content and cell death.

Pharmacodynamics

The majority of pathogenic yeasts and molds including genera Candida, Aspergillus, Cephalosporium, Fusarium and Penicillium are sensitive to natamycin. Dermatophytes and Pseudoallescheria boydii are less sensitive to natamycin. Cases of resistance to natamycin in clinical practice have not been noted. Natamycin in the dosage form of enteric coated tablets acts only in the intestinal lumen.

Pharmacokinetics

In oral administration natamycin is practically not absorbed from the gastrointestinal tract and has no systemic action.

Indications

Active ingredient

Composition

Active substances:

Natamycin 100 mg.

Auxiliary substances:

Potato starch – 79.2 mg,

povidone K30 – 5 mg,

magnesium stearate – 2.5 mg,

lactose monohydrate – 66 mg.

Composition of the shell:

cellacephate – 18 mg,

triacetin – 2.7 mg,

p> sucrose – 122 mg,

methylparahydroxybenzoate – 0.07 mg,

calcium carbonate – 30 mg,

kaolin – 14.2 mg,

talc – 21.7 mg,

titanium dioxide – 3 mg,

acacia gum – 7.3 mg,

gelatin – 3.3 mg,

beeswax white – 0.13 mg.

How to take, the dosage

The drug is taken orally. Food intake has no effect on the effectiveness of the drug.

The dosage regimen for different age groups and depending on the disease

In intestinal candidiasis:

Pimafucin® tablets (orally 100 mg (1 tablet) 4 times a day for 10 – 20 days) may be used together with antifungal drugs (for example, Pimafucin® suppositories) for sanation of the focus of candida infection in the intestine.

The duration of treatment is determined individually. After disappearance of symptoms it is recommended to continue treatment for a few more days.

Interaction

Drug interactions of Pimafucin® with other medicinal products were not detected.

Special Instructions

Patients with rare congenital galactose intolerance, fructose intolerance, lactase lapp deficiency, glucose-galactose malabsorption or sucrose-isomaltase deficiency should take into account that the drug contains lactose monohydrate (66 mg) and sucrose (122 mg). If the patient suffers from one of the above mentioned diseases, before taking Pimafucin® tablets, it is necessary to consult a doctor.

Pimafucin® in this dosage form is not recommended for use in infants because of possible difficulty in swallowing the pills.

Impact on ability to drive vehicles and other mechanisms requiring increased concentration

Pimafucin® does not affect the ability to drive vehicles and mechanisms.

Interaction with alcohol

There are no data on interaction with alcohol.

Prescription conditions from pharmacies

The drug is approved for over-the-counter use.

Contraindications

Side effects

When using Pimafucin:

In the digestive system: nausea, diarrhea may occur (occurring in the first days of taking the drug and passing on its own during treatment).

The patient should be warned that if any of the side effects mentioned in the instructions worsen, or if he notices any other side effects not mentioned in the instructions, he should tell his doctor.

Overdose

At present, no cases of overdose of Pimafucin® have been reported.

Similarities